
Astellas follows up $3B gene therapy buyout with $109M plan to accelerate a manufacturing boom
Just weeks after closing on their $3 billion Audentes buyout, Astellas is following up with a $109 million plan to build a new manufacturing facility in order to become a player in the booming gene therapy field.
Astellas is building out a 135,000-square-foot plant from the ground up, with plans to add 200 jobs in Sanford, NC, a region that has become home to a thriving hub of drug-making operations. Like a number of startups in the field, Audentes has been pursuing AAV programs fashioned with tech originally designed by Penn’s Jim Wilson.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.